Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma
NCT03385226Phase 2Active, not recruiting
- Sponsor
- University College London
- Start
- Jan 2019
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cutaneous T-cell lymphoma (CTCL), sponsored by University College London. Started Jan 2019; status: active, not recruiting.
02
Drugs
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03385226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385226.